Tirzepatide wins on raw weight loss (22.5% body weight at 72 weeks in SURMOUNT-1 vs ~15% for semaglutide at 68 weeks in STEP-1) and works through two pathways instead of one. Semaglutide wins on real-world track record (FDA-approved 2017 for diabetes, 2021 for obesity), broader insurance coverage, and the only oral GLP-1 pill option (Rybelsus). For most cash-pay patients in June 2026, the cheapest legitimate path is compounded — Embody from $69/month for semaglutide or $119/month for tirzepatide (advertised starting rates; some checkout funnels quote about $99/$149 month-to-month), SnagRx at $69/month on the 12-month plan, or TrimRx at $179/month flat (Provider record). Here's the molecule-by-molecule head-to-head: how they work, the trial data side by side, side effect profiles, and the cheapest legitimate path for each by your insurance and budget.
Quick answer: which should you pick?
| Your situation | Pick | Cheapest path |
|---|---|---|
| Maximum weight loss, no clinical reason to favor sema | Tirzepatide | Embody $69/mo compounded; or Zepbound Savings Card $25/mo if insured |
| Commercially insured + Type 2 diabetes | Semaglutide (Ozempic) | Ozempic Savings Card $25/mo |
| Commercially insured + obesity, no T2D | Either, based on what's on formulary | Wegovy or Zepbound Savings Card at $25/mo |
| Medicare Part D + qualifying conditions | Either | Medicare Bridge $50/mo (Wegovy, Zepbound, or Foundayo) |
| Cash-pay, prefer oral over injection | Semaglutide (Rybelsus tablets) or Foundayo (orforglipron, a different molecule) | Foundayo $149–$299/mo |
| Cash-pay, want lowest cost | Either (same compounded price floor) | Embody $69/mo |
| History of bad GI side effects on semaglutide | Tirzepatide | Same-molecule continuation via TrimRx |
How they actually work: mechanism difference matters
Semaglutide is a single-receptor agonist. It binds the GLP-1 receptor only, mimicking glucagon-like peptide-1 — a gut hormone released after eating that slows stomach emptying, signals fullness to the brain, and triggers insulin release. Half-life is roughly 1 week (weekly injection works).
Tirzepatide is a dual-receptor agonist. It binds both the GLP-1 receptor AND the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a second incretin hormone with effects on insulin secretion, fat metabolism, and (debated) appetite. The dual mechanism explains why tirzepatide produces meaningfully more weight loss in head-to-head trials.
Why this matters clinically: if semaglutide didn't work for you, tirzepatide may — it recruits a separate pathway. If semaglutide worked but you plateaued, escalating to tirzepatide is a defensible next step.
Weight loss: trial data side by side
| Trial | Drug | Dose | Body weight loss | Duration |
|---|---|---|---|---|
| STEP-1 (2021) | Semaglutide | 2.4 mg/wk | 14.9% | 68 weeks |
| STEP-3 (2021) | Semaglutide + lifestyle | 2.4 mg/wk | 16.0% | 68 weeks |
| SURMOUNT-1 (2022) | Tirzepatide | 15 mg/wk | 22.5% | 72 weeks |
| SURMOUNT-3 (2023) | Tirzepatide | 15 mg/wk | 21.1% (after lifestyle) | 72 weeks |
| SURMOUNT-5 (2025) | Tirzepatide vs semaglutide head-to-head | 15 mg vs 2.4 mg | 20.2% vs 13.7% | 72 weeks |
The SURMOUNT-5 head-to-head (published 2025) is the cleanest comparison: same population, same trial design, both drugs at their FDA-approved max doses for obesity. Tirzepatide produced about 47% more weight loss in absolute terms.
Caveat: trial averages are not your personal result. Both molecules have a long tail — some patients on semaglutide lose >20%, some patients on tirzepatide lose <10%. Genetics, baseline metabolism, dose tolerance, and lifestyle adherence all matter more than which molecule you chose.
Side effects: more similar than different (with one exception)
Both molecules share the same GI-dominant side effect profile because they share the GLP-1 mechanism: nausea, diarrhea, constipation, vomiting, decreased appetite. Most are dose-dependent and resolve as you titrate up slowly.
Where they differ:
- Constipation: somewhat more common on tirzepatide (the GIP receptor effects on gut motility appear additive).
- Severe nausea requiring discontinuation: roughly comparable across trials (4-7% on both at top dose).
- Injection site reactions: equivalent.
- Rare but serious: both carry boxed warnings for thyroid C-cell tumors (rodent data; human risk unestablished). Both should be avoided with personal/family history of medullary thyroid carcinoma or MEN 2 syndrome.
For a deeper safety read, see our Ozempic long-term safety analysis — the cardiovascular and kidney protection data applies meaningfully to both molecules.
Brand names: who makes what
| Brand | Molecule | Manufacturer | FDA indication | Form |
|---|---|---|---|---|
| Ozempic | Semaglutide | Novo Nordisk | Type 2 diabetes | Weekly injection |
| Wegovy | Semaglutide | Novo Nordisk | Obesity | Weekly injection + daily tablet |
| Rybelsus | Semaglutide | Novo Nordisk | Type 2 diabetes | Daily oral pill |
| Mounjaro | Tirzepatide | Eli Lilly | Type 2 diabetes | Weekly injection |
| Zepbound | Tirzepatide | Eli Lilly | Obesity | Weekly injection + KwikPen + daily tablet |
Practical implication: if your prescriber wrote you a tirzepatide prescription for weight loss, the on-label version is Zepbound (not Mounjaro). If they wrote Mounjaro off-label, see our Mounjaro for weight loss guide for the cost optimization paths. If they wrote semaglutide for weight loss, the on-label version is Wegovy (not Ozempic).
Cost comparison: every legitimate path in June 2026
Semaglutide paths
| Source | Monthly cost | Eligibility |
|---|---|---|
| Ozempic Savings Card | $25/mo | Commercial insurance + Type 2 diabetes |
| Wegovy Savings Card | $25/mo | Commercial insurance + Wegovy on formulary |
| Medicare Bridge (Wegovy) | $50/mo from Jul 1 | Part D + qualifying tier |
| NovoCare cash-pay (Wegovy) | $199–$349/mo pen; pill from $149/mo | None — direct from Novo |
| Compounded semaglutide | $99-$249/mo | Cash-pay, no diagnosis required |
| Foundayo (oral, same drug class) | $149–$299/mo | Telehealth prescription |
| Brand Wegovy retail | $1,349/mo | Cash, no programs applied |
| Brand Ozempic retail | $998/mo | Cash, no programs applied |
Full breakdown: How to Get Wegovy Cheaper and Cheapest Compounded Semaglutide.
Tirzepatide paths
| Source | Monthly cost | Eligibility |
|---|---|---|
| Mounjaro Savings Card | $25/mo | Commercial insurance + Type 2 diabetes |
| Zepbound Savings Card | $25/mo | Commercial insurance + Zepbound on formulary |
| Medicare Bridge (Zepbound) | $50/mo from Jul 1 | Part D + qualifying tier |
| LillyDirect Zepbound vials | $299-$449/mo | None — direct from Lilly |
| Compounded tirzepatide | $99-$249/mo | Cash-pay, no diagnosis required |
| Brand Zepbound retail | $1,086/mo | Cash, no programs applied |
| Brand Mounjaro retail | $1,112/mo | Cash, no programs applied |
Full breakdown: How to Get Zepbound Cheaper, Cheapest Compounded Tirzepatide, and Mounjaro Off-Label Weight Loss.
Key observation: at the compounded floor, both molecules are priced identically ($99-$249/mo depending on provider). Cost is no longer a tiebreaker between sema and tirz for cash-pay patients. The real decision is which molecule clinically fits, which provider you trust, and whether your insurance unlocks a brand savings card path.
Which compounded providers offer what?
All five tracked programs offer both semaglutide and tirzepatide (with one exception). Ranked commission-first:
- TrimRx — Provider record. Semaglutide $179/mo, tirzepatide $259/mo. Flat all-inclusive pricing at any dose. Best for switchers.
- Embody. Semaglutide from $69/mo (injection), tirzepatide from $119/mo. Cheapest floor; oral GLP-1 gum option for needle-averse patients.
- SnagRx. Semaglutide $69/mo, tirzepatide $119/mo on the 12-month plan ($99/$149 month-to-month), locked in for life so the rate never rises as your dose climbs. LegitScript-certified.
- bmiMD. Semaglutide $119/mo, tirzepatide $179/mo on the 12-month plan ($159/$249 month-to-month). Not available in Louisiana or Mississippi.
- ShedRx. Semaglutide $159/mo, tirzepatide $239/mo on the 12-month plan ($199/$299 monthly, 2-month minimum). Ships to all 50 states, with a brand-name pathway to FDA-approved Wegovy or Zepbound.
For the full compounded grid see our cheapest compounded semaglutide ranking and cheapest compounded tirzepatide ranking.
Regulatory caveat: the FDA's June 29 compounded comment period
If you're choosing between brand and compounded right now, you should know: the FDA proposed on May 1, 2026 to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The comment period closed June 29, 2026. If finalized, 503B large-batch compounding ends — 503A patient-specific compounding continues under separate rules.
Practical implication for the sema-vs-tirz decision: the regulatory risk is identical for both molecules — the proposed rule covers them equally. Don't pick semaglutide hoping it'll dodge enforcement; the FDA is treating them as a class.
Full analysis: FDA 503B Compounded Ban Explainer.
Switching molecules: dose conversion
If you've been on semaglutide and want to try tirzepatide (or vice versa), the molecules are not interchangeable mg-for-mg. Standard transition protocol:
Semaglutide → Tirzepatide. Start at tirzepatide 2.5 mg/week (the standard starter dose) even if you were at semaglutide max (2.4 mg). Tirzepatide's titration is faster (every 4 weeks) but each step is a meaningful jump. Most patients reach 7.5-10 mg before deciding whether to escalate further.
Tirzepatide → Semaglutide. Same logic in reverse. Start semaglutide at 0.25 mg/week regardless of your prior tirzepatide dose. The receptors and tolerability profile reset.
Same-molecule continuation (e.g., brand Ozempic to compounded semaglutide): 1:1 mg conversion, no titration restart. See our switching guide for the full Ozempic-to-compounded protocol — the same logic applies to brand-to-compounded transitions for tirzepatide.
Decision matrix: pick the right molecule for your situation
You have Type 2 diabetes and commercial insurance: Semaglutide via Ozempic Savings Card ($25/mo) — broadest insurance coverage, 7+ years of T2D data. If A1C isn't controlling on max semaglutide, talk to your prescriber about switching to tirzepatide via Mounjaro Savings Card (also $25/mo).
You have obesity and your plan covers Wegovy OR Zepbound: Pick whichever is on your formulary. Both Savings Cards drop you to $25/mo. Most plans cover one but not both.
You're cash-pay and want maximum weight loss: Tirzepatide via compounded (Embody from $119/mo, bmiMD $179/mo on the 12-month plan, TrimRx $259/mo flat).
You're cash-pay and want the lowest monthly cost: Either molecule via Embody at $69/mo for semaglutide or $119/mo for tirzepatide — same provider, same credentialing tier, you choose the molecule.
You're cash-pay and need an oral option: Foundayo (orforglipron) at $149–$299/mo by dose, Wegovy tablets at $1,349 retail ($25 with insurance), or Rybelsus daily pill. No oral tirzepatide on the market yet (Lilly's orforglipron is a separate molecule that just launched — see our Foundayo launch post).
You're on Medicare Part D and qualify for the Bridge Program: Either molecule via Wegovy or Zepbound at $50/mo from July 1. See our Medicare Bridge enrollment guide for the tier requirements.
FAQ
Is tirzepatide better than semaglutide for weight loss? At their FDA-approved max doses (15 mg tirzepatide vs 2.4 mg semaglutide), tirzepatide produces more weight loss on average — about 20% vs 14% in SURMOUNT-5's head-to-head trial. Individual results vary significantly.
Can I switch from semaglutide to tirzepatide? Yes. Start at tirzepatide 2.5 mg/week regardless of your prior semaglutide dose. Most prescribers titrate every 4 weeks based on tolerance and weight response.
Is compounded tirzepatide as effective as Mounjaro/Zepbound? The active molecule is the same. Clinical effect depends on dose, adherence, and titration — not on whether the pharmacy is Eli Lilly or a US 503A compounder. Real-world adherence is often higher on compounded programs because the cost barrier is lower.
Which has worse side effects? Very similar profiles (both GLP-1-driven). Tirzepatide has slightly higher rates of constipation; semaglutide and tirzepatide are roughly equivalent on nausea, diarrhea, vomiting, and injection site reactions.
Is one safer for long-term use? Both have boxed warnings for thyroid C-cell tumors (rodent data; human risk unestablished). Both have cardiovascular outcome trials showing benefit in their respective populations. The 90,000-patient long-term data we cover in our Ozempic long-term safety analysis applies meaningfully to both molecules.
What about Foundayo (orforglipron)? Foundayo is a third molecule — a small-molecule oral GLP-1 receptor agonist from Eli Lilly. Not a tirzepatide or semaglutide; a separate drug. Up to 12.4% body weight loss at the top dose in ATTAIN-1 (below both semaglutide and tirzepatide). Launched April 2026 at $149–$299/mo cash-pay, priced by dose. See our Foundayo launch post for the full breakdown.
Will FDA pull compounded tirzepatide or semaglutide first? The FDA's May 2026 proposal treats both molecules identically — comment period closes June 29, 2026, with a final rule expected late 2026 at the earliest. Neither molecule has a regulatory edge over the other for compounded patients.
For our full provider grid see the cheapest GLP-1 programs page. For the long-term cardiovascular and kidney case for staying on a GLP-1, see our 90,000-patient analysis. For switching from brand to compounded, see our step-by-step switching guide.